The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Clinical research

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial

EuroIntervention 2010;6:437-446 - DOI10.4244/EIJV6I4A75.

1. Wake Forest University Health Sciences, Medical Center Blvd., Winston-Salem, NC, USA; 2. The Heart Center of IN, Indianapolis, IN, USA; 3. St. Patrick Hospital, Missoula, MT, USA; 4. Abbott Vascular, Santa Clara, CA, USA; 5. Columbia University Medical

Aims: To examine the two year clinical outcomes in dual-vessel disease from the SPIRIT III trial comparing the XIENCE V® everolimus-eluting stent (EES) to the

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial